1. Phylogeny  
Tyrosine‑protein kinase ITK (also known as Interleukin‑2‑inducible T‑cell kinase, Kinase EMT, T‑cell‑specific kinase, and Tyrosine‑protein kinase Lyk; gene: ITK) is classified as a member of the Tec family of non‑receptor tyrosine kinases. This family, which includes related kinases such as Bruton’s tyrosine kinase (BTK), TEC, BMX, and RLK/Txk, is characterized by a conserved modular structure that is distinct from the Src family. ITK orthologs have been reported across a wide range of mammalian species as well as in earlier vertebrate lineages, indicating that the catalytic core and regulatory architecture of ITK are evolutionarily conserved and have been maintained through vertebrate evolution due to their essential role in regulating lymphocyte development and function (zhong2014targetinginterleukin2inducibletcell pages 11-13, devkota2017anautoinhibitoryrole pages 1-3). Comprehensive kinome analyses have established that the Tec family emerged early in vertebrate evolution, forming an independent branch within the human kinome dedicated largely to the regulation of adaptive immune responses.

2. Reaction Catalyzed  
ITK functions as a tyrosine kinase by catalyzing a phosphorylation reaction in which the γ‑phosphate group from adenosine triphosphate (ATP) is transferred to a specific tyrosine residue on a protein substrate. The general catalytic reaction can be represented as:  
  ATP + protein-(L-tyrosine) = ADP + protein-(L-tyrosine-phosphate) + H⁺.  
This ATP-dependent phosphoryl transfer is critical for initiating and propagating the intracellular signaling cascades that follow T‑cell receptor (TCR) engagement (zhong2014targetinginterleukin2inducibletcell pages 11-13).

3. Cofactor Requirements  
The catalytic activity of ITK, like that of all ATP-dependent kinases, is dependent on the presence of divalent metal ion cofactors. Specifically, magnesium ions (Mg²⁺) are required to coordinate the negatively charged phosphate groups of ATP and facilitate the positioning of ATP for the phosphoryl transfer reaction. The presence of Mg²⁺ stabilizes the ATP binding within the active site of ITK, thus ensuring optimal catalytic performance during the phosphorylation process (zhong2014targetinginterleukin2inducibletcell pages 11-13, howe2019magnesiumrestoresactivity pages 7-8).

4. Substrate Specificity  
ITK exhibits substrate specificity that is finely tuned to its central role within T‑cell receptor signaling. It preferentially phosphorylates tyrosine residues on proteins that function in the propagation of signals downstream of T‑cell activation. Key substrates of ITK include phospholipase C gamma 1 (PLCG1), which requires phosphorylation for activation; once phosphorylated, PLCG1 catalyzes the hydrolysis of its lipid substrate to generate inositol trisphosphate (IP₃) and diacylglycerol (DAG), thereby mobilizing intracellular calcium. In addition, ITK phosphorylates the adaptor protein LAT (linker for activation of T cells), which serves as a scaffold for the assembly of multiprotein complexes, as well as LCP2 (also known as SLP‑76), which further propagates downstream signaling events. ITK is also reported to phosphorylate the transcription factor TBX21 (T‑bet) at Tyr‑530, thereby regulating its interaction with the transcriptional partner GATA3. Although no single consensus sequence has been firmly delineated, the overall substrate preference reflects a tendency to target tyrosine residues that reside within motifs present in proteins that are central to the T‑cell activation process (basu2023gapjunctionalintercellular pages 163-165, kannan2015requirementforitk pages 8-9).

5. Structure  
The three‑dimensional structure of ITK is defined by a modular organization of evolutionarily conserved domains that determine both its catalytic function and regulatory dynamics. The N‑terminal region is composed of a Pleckstrin Homology (PH) domain, which binds phosphoinositide lipids such as phosphatidylinositol 3,4,5‑trisphosphate (PIP₃) generated by PI3 kinase. This interaction is essential for the translocation of ITK to the plasma membrane during T‑cell activation (zhong2014targetinginterleukin2inducibletcell pages 11-13, huang2014functionofil2inducible pages 11-15). Adjacent to the PH domain is the Tec Homology (TH) domain, which includes a zinc‑binding Btk Homology (BH) motif along with multiple proline‑rich regions. The TH domain contributes to the structural stability of ITK and may facilitate oligomerization while also participating in intramolecular interactions that maintain ITK in an autoinhibited state under resting conditions (devkota2017anautoinhibitoryrole pages 1-3, huang2014functionofil2inducibleb pages 11-15).  
Following the TH domain, ITK contains an Src Homology 3 (SH3) domain that binds proline‑rich sequences within both its own structure and in interacting proteins, and an Src Homology 2 (SH2) domain, which mediates interactions with phosphotyrosine motifs on partner proteins. The C‑terminal region is occupied by the kinase domain (also referred to as the SH1 domain), which houses the active site responsible for catalysis. Within the kinase domain, structural motifs such as the activation loop — featuring a critical tyrosine residue at position 511 — the hydrophobic spine, and the C‑helix play pivotal roles in the regulation of enzymatic activity. Phosphorylation of the activation loop residue (Y511) by upstream kinases such as LCK disrupts autoinhibitory contacts and stabilizes the active conformation of ITK. In addition, autophosphorylation events, including phosphorylation of tyrosine 180 within the SH3 domain, further modulate substrate binding and catalytic efficiency. Structure-based inhibitor design studies, including those employing benzothiazole-based compounds, have underscored the importance of the ATP‑binding pocket within the kinase domain for achieving high specificity toward ITK (mackinnon2013structurebaseddesignand pages 5-5, huang2014functionofil2induciblec pages 11-15).

6. Regulation  
ITK activity is governed by a series of regulatory mechanisms that ensure its activity is tightly coupled to T‑cell receptor (TCR) engagement. In resting T cells, intramolecular interactions among the PH, TH, SH3, and SH2 domains maintain ITK in an autoinhibited, closed conformation. Upon TCR stimulation, activation of PI3 kinase results in the generation of PIP₃ at the plasma membrane, allowing the PH domain of ITK to bind these lipids and drive its translocation to the membrane where its substrates are located (hsu2023selectiveinhibitionof pages 3-5, zhong2014targetinginterleukin2inducibletcell pages 11-13).  
The next critical step in ITK activation is mediated by LCK, a Src family kinase that phosphorylates the activation loop tyrosine (Y511) within the kinase domain. This phosphorylation event relieves autoinhibitory contacts and primes ITK for full catalytic activity. Subsequent autophosphorylation on additional sites, such as tyrosine 180 in the SH3 domain, further enhances ITK’s enzymatic activity and its ability to engage with adaptor proteins (devkota2017anautoinhibitoryrole pages 3-4, kannan2015requirementforitk pages 9-11, hsu2023selectiveinhibitionof pages 16-20).  
Moreover, allosteric regulation is achieved through conformational shifts that are induced upon ligand binding and intramolecular domain rearrangement. The interplay between the PH domain and the catalytic domain, together with the disruption of autoinhibitory interactions mediated by the SH3 and proline‑rich regions, facilitates the transition of ITK from a closed, inactive state to an open, active conformation (devkota2017anautoinhibitoryrole pages 22-23, hsu2023selectiveinhibitionof pages 16-20).

7. Function  
ITK is an indispensable mediator of adaptive immune response, with its function predominantly linked to T‑cell receptor (TCR) signaling. ITK is selectively expressed in T lymphocytes, including conventional αβ T cells, gamma‑delta T cells, and natural killer T (NKT) cells, and its expression is pivotal for the development, differentiation, and function of these cells. Following antigen recognition by T cells, ITK is rapidly recruited to the plasma membrane where it becomes activated through phosphorylation by LCK. Once activated, ITK phosphorylates several key substrates that facilitate further signal propagation. For example, the phosphorylation of phospholipase C gamma 1 (PLCG1) by ITK activates its lipase activity, leading to the hydrolysis of phosphatidylinositol 4,5‑bisphosphate (PIP₂) into the second messengers inositol trisphosphate (IP₃) and diacylglycerol (DAG). The resulting IP₃ triggers the release of Ca²⁺ from the endoplasmic reticulum, which in turn supports sustained calcium influx and the nuclear translocation of the transcription factor NFAT necessary for lymphokine production (zhong2014targetinginterleukin2inducibletcell pages 11-13).  
In addition to PLCG1, ITK phosphorylates adaptor proteins such as LAT and LCP2 (also known as SLP‑76), which function as scaffolds to recruit other signaling molecules—including VAV1—thereby amplifying signals that drive T‑cell proliferation and differentiation. Furthermore, ITK also targets the transcription factor TBX21 (T‑bet) at Tyr‑530; this post‑translational modification modulates TBX21’s interaction with GATA3, thereby influencing the differentiation program of T‑helper cells. Collectively, these phosphorylation events are essential for mediating intracellular signaling that controls cytokine production, T‑cell proliferation, and the differentiation of naïve T cells into specialized subsets (zhong2014targetinginterleukin2inducibletcell pages 11-13, kannan2015requirementforitk pages 8-9, huang2014functionofil2induciblea pages 11-15, lechner2020roleofthe pages 7-8).

8. Other Comments  
Given the central role of ITK in T‑cell activation and adaptive immunity, the kinase has emerged as a critical target for pharmaceutical intervention in immune‑mediated disorders. Several selective inhibitors have been developed targeting ITK’s ATP‑binding site, including both covalent and non‑covalent compounds. Structure‑based drug design studies have led to the development of benzothiazole‑based inhibitors, which demonstrate sub‑nanomolar potency and high specificity by interacting with residues that are unique to ITK’s active site (kaur2012inhibitorsofinterleukin2 pages 1-2, mackinnon2013structurebaseddesignand pages 5-5, hsu2023selectiveinhibitionof pages 14-16). Dysregulation of ITK activity has been implicated in a range of immune‑mediated disorders, including autoimmune diseases, allergic asthma, and certain lymphoproliferative disorders. In clinical and pre‑clinical studies, abnormal ITK signaling has been associated with conditions in which T‑cell activation is misregulated, and ITK deficiency or altered activity can lead to immunodeficiency phenotypes characterized by impaired T‑cell activation. As such, pharmacological modulation of ITK is seen as a promising strategy to correct aberrant T‑cell responses in diseases where excessive or deficient immune activation is observed (lechner2020roleofthe pages 7-8, kaur2012inhibitorsofinterleukin2 pages 1-2, hsu2023selectiveinhibitionof pages 14-16).

9. References  
zhong2014targetinginterleukin2inducibletcell pages 11-13, devkota2017anautoinhibitoryrole pages 1-3, howe2019magnesiumrestoresactivity pages 7-8, basu2023gapjunctionalintercellular pages 163-165, kaur2012inhibitorsofinterleukin2 pages 1-2, lechner2020roleofthe pages 7-8, mackinnon2013structurebaseddesignand pages 5-5, huang2014functionofil2inducible pages 11-15, huang2014functionofil2induciblea pages 11-15, huang2014functionofil2inducibleb pages 11-15, huang2014functionofil2induciblec pages 11-15, huang2014functionofil2inducibled pages 11-15, huang2014functionofil2inducibled pages 15-19, huang2014functionofil2induciblee pages 11-15, huang2014functionofil2induciblee pages 15-19, huang2014functionofil2induciblef pages 11-15, huang2014functionofil2induciblef pages 15-19, hsu2023selectiveinhibitionof pages 3-5, hsu2023selectiveinhibitionof pages 16-20, kannan2015requirementforitk pages 8-9, kannan2015requirementforitk pages 9-11

References

1. (zhong2014targetinginterleukin2inducibletcell pages 11-13): Y. Zhong, A. Johnson, J. Byrd, and J. Dubovsky. Targeting interleukin-2-inducible t-cell kinase (itk) in t-cell related diseases. Postdoc journal : a journal of postdoctoral research and postdoctoral affairs, 2 6:1-11, Jun 2014. URL: https://doi.org/10.14304/surya.jpr.v2n6.1, doi:10.14304/surya.jpr.v2n6.1. This article has 29 citations.

2. (basu2023gapjunctionalintercellular pages 163-165): I Basu. Gap junctional intercellular communication: role of cx43 phosphorylation by tyrosine kinases. Unknown journal, 2023.

3. (devkota2017anautoinhibitoryrole pages 1-3): Sujan Devkota, Raji E. Joseph, Scott E. Boyken, D. Bruce Fulton, and Amy H. Andreotti. An autoinhibitory role for the pleckstrin homology domain of interleukin-2-inducible tyrosine kinase and its interplay with canonical phospholipid recognition. Biochemistry, 56:2938-2949, May 2017. URL: https://doi.org/10.1021/acs.biochem.6b01182, doi:10.1021/acs.biochem.6b01182. This article has 23 citations and is from a peer-reviewed journal.

4. (devkota2017anautoinhibitoryrole pages 22-23): Sujan Devkota, Raji E. Joseph, Scott E. Boyken, D. Bruce Fulton, and Amy H. Andreotti. An autoinhibitory role for the pleckstrin homology domain of interleukin-2-inducible tyrosine kinase and its interplay with canonical phospholipid recognition. Biochemistry, 56:2938-2949, May 2017. URL: https://doi.org/10.1021/acs.biochem.6b01182, doi:10.1021/acs.biochem.6b01182. This article has 23 citations and is from a peer-reviewed journal.

5. (devkota2017anautoinhibitoryrole pages 3-4): Sujan Devkota, Raji E. Joseph, Scott E. Boyken, D. Bruce Fulton, and Amy H. Andreotti. An autoinhibitory role for the pleckstrin homology domain of interleukin-2-inducible tyrosine kinase and its interplay with canonical phospholipid recognition. Biochemistry, 56:2938-2949, May 2017. URL: https://doi.org/10.1021/acs.biochem.6b01182, doi:10.1021/acs.biochem.6b01182. This article has 23 citations and is from a peer-reviewed journal.

6. (howe2019magnesiumrestoresactivity pages 7-8): Matthew K. Howe, Kennichi Dowdell, Amitava Roy, Julie E. Niemela, Wyndham Wilson, Joshua J. McElwee, Jason D. Hughes, and Jeffrey I. Cohen. Magnesium restores activity to peripheral blood cells in a patient with functionally impaired interleukin-2-inducible t cell kinase. Frontiers in Immunology, Aug 2019. URL: https://doi.org/10.3389/fimmu.2019.02000, doi:10.3389/fimmu.2019.02000. This article has 16 citations and is from a peer-reviewed journal.

7. (hsu2023selectiveinhibitionof pages 14-16): Lih-Yun Hsu, James T Rosenbaum, Erik Verner, William B Jones, Craig M. Hill, James W. Janc, Joseph J. Buggy, Ning Ding, John C. Reneau, Michael S. Khodadoust, Youn H. Kim, Ryan A. Wilcox, and Richard A. Miller. Selective inhibition of interleukin-2 inducible t cell kinase (itk) enhances anti-tumor immunity in association with th1-skewing, cytotoxic t cell activation, and reduced t cell exhaustion. BioRxiv, Jul 2023. URL: https://doi.org/10.1101/2023.07.05.547822, doi:10.1101/2023.07.05.547822. This article has 2 citations.

8. (hsu2023selectiveinhibitionof pages 16-20): Lih-Yun Hsu, James T Rosenbaum, Erik Verner, William B Jones, Craig M. Hill, James W. Janc, Joseph J. Buggy, Ning Ding, John C. Reneau, Michael S. Khodadoust, Youn H. Kim, Ryan A. Wilcox, and Richard A. Miller. Selective inhibition of interleukin-2 inducible t cell kinase (itk) enhances anti-tumor immunity in association with th1-skewing, cytotoxic t cell activation, and reduced t cell exhaustion. BioRxiv, Jul 2023. URL: https://doi.org/10.1101/2023.07.05.547822, doi:10.1101/2023.07.05.547822. This article has 2 citations.

9. (hsu2023selectiveinhibitionof pages 3-5): Lih-Yun Hsu, James T Rosenbaum, Erik Verner, William B Jones, Craig M. Hill, James W. Janc, Joseph J. Buggy, Ning Ding, John C. Reneau, Michael S. Khodadoust, Youn H. Kim, Ryan A. Wilcox, and Richard A. Miller. Selective inhibition of interleukin-2 inducible t cell kinase (itk) enhances anti-tumor immunity in association with th1-skewing, cytotoxic t cell activation, and reduced t cell exhaustion. BioRxiv, Jul 2023. URL: https://doi.org/10.1101/2023.07.05.547822, doi:10.1101/2023.07.05.547822. This article has 2 citations.

10. (huang2014functionofil2inducible pages 11-15): W Huang. Function of il-2-inducible t cell kinase (itk) in innate t cells and mast cells. Unknown journal, 2014.

11. (huang2014functionofil2induciblea pages 11-15): W Huang. Function of il-2-inducible t cell kinase (itk) in innate t cells and mast cells. Unknown journal, 2014.

12. (huang2014functionofil2inducibleb pages 11-15): W Huang. Function of il-2-inducible t cell kinase (itk) in innate t cells and mast cells. Unknown journal, 2014.

13. (huang2014functionofil2induciblec pages 11-15): W Huang. Function of il-2-inducible t cell kinase (itk) in innate t cells and mast cells. Unknown journal, 2014.

14. (huang2014functionofil2inducibled pages 11-15): W Huang. Function of il-2-inducible t cell kinase (itk) in innate t cells and mast cells. Unknown journal, 2014.

15. (huang2014functionofil2inducibled pages 15-19): W Huang. Function of il-2-inducible t cell kinase (itk) in innate t cells and mast cells. Unknown journal, 2014.

16. (huang2014functionofil2induciblee pages 11-15): W Huang. Function of il-2-inducible t cell kinase (itk) in innate t cells and mast cells. Unknown journal, 2014.

17. (huang2014functionofil2induciblee pages 15-19): W Huang. Function of il-2-inducible t cell kinase (itk) in innate t cells and mast cells. Unknown journal, 2014.

18. (huang2014functionofil2induciblef pages 11-15): W Huang. Function of il-2-inducible t cell kinase (itk) in innate t cells and mast cells. Unknown journal, 2014.

19. (huang2014functionofil2induciblef pages 15-19): W Huang. Function of il-2-inducible t cell kinase (itk) in innate t cells and mast cells. Unknown journal, 2014.

20. (kannan2015requirementforitk pages 8-9): A Kannan. Requirement for itk kinase activity for th1, th2, th17 and inkt cell cytokine production revealed by an allele sensitive mutant. Unknown journal, 2015.

21. (kannan2015requirementforitk pages 9-11): A Kannan. Requirement for itk kinase activity for th1, th2, th17 and inkt cell cytokine production revealed by an allele sensitive mutant. Unknown journal, 2015.

22. (kaur2012inhibitorsofinterleukin2 pages 1-2): Maninder Kaur, Malkeet Singh Bahia, and Om Silakari. Inhibitors of interleukin-2 inducible t-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 47 3:574-88, Oct 2012. URL: https://doi.org/10.1016/j.ejps.2012.07.013, doi:10.1016/j.ejps.2012.07.013. This article has 28 citations.

23. (lechner2020roleofthe pages 7-8): Kristina S. Lechner, Markus F. Neurath, and Benno Weigmann. Role of the il-2 inducible tyrosine kinase itk and its inhibitors in disease pathogenesis. Journal of Molecular Medicine, 98:1385-1395, Aug 2020. URL: https://doi.org/10.1007/s00109-020-01958-z, doi:10.1007/s00109-020-01958-z. This article has 55 citations.

24. (mackinnon2013structurebaseddesignand pages 5-5): Colin H. MacKinnon, Kevin Lau, Jason D. Burch, Yuan Chen, Jonathon Dines, Xiao Ding, Charles Eigenbrot, Alexander Heifetz, Allan Jaochico, Adam Johnson, Joachim Kraemer, Susanne Kruger, Thomas M. Krülle, Marya Liimatta, Justin Ly, Rosemary Maghames, Christian A.G.N. Montalbetti, Daniel F. Ortwine, Yolanda Pérez-Fuertes, Steven Shia, Daniel B. Stein, Giancarlo Trani, Darshan G. Vaidya, Xiaolu Wang, Steven M. Bromidge, Lawren C. Wu, and Zhonghua Pei. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible t cell kinase (itk). Bioorganic &amp; Medicinal Chemistry Letters, 23:6331-6335, Dec 2013. URL: https://doi.org/10.1016/j.bmcl.2013.09.069, doi:10.1016/j.bmcl.2013.09.069. This article has 18 citations.